Subscribe Us

header ads

Recents

header ads

Cancer Therapeutics and Biotherapeutics Market Size, Growth, Demands Outlook and Forecasts to 2030

Precedence Research - January 31, 2023

According to the research report, the global cancer therapeutics and biotherapeutics market size is expected to touch USD 339.44 Billion by 2030, from USD 175.14 Billion in 2022, growing with a significant CAGR of 8.6% from 2022 to 2030. 

Cancer Therapeutics and Biotherapeutics Market Size 2021 to 2030

The cancer therapeutics and biotherapeutics report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global cancer therapeutics and biotherapeutics in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global cancer therapeutics and biotherapeutics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global cancer therapeutics and biotherapeutics during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1657

 Report Scope of the Cancer Therapeutics and Biotherapeutics Market

Report CoverageDetails
Market Size by 2030USD 339.44 Billion
Growth Rate from 2022 to 2030

CAGR of 8.6%

Largest MarketNorth America
Fastest Growing MakretAsia Pacific
Base Year2021
Forecast Period2022 to 2030
Segments CoveredApplication, Top Selling Drugs, End User, Product, Geography

This study covers a detailed segmentation of the global cancer therapeutics and biotherapeutics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global cancer therapeutics and biotherapeutics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • Amgen Inc.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • ELI Lilly and Company
  • Hoffmann-La Roche AG
  • EnGeneIC Ltd
  • Merck & Co Inc.
  • Novartis
  • Pfizer Inc.
  • Johnson & Johnson

Market Segmentation

 By Application

  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Cervical Cancer
  • Head and Neck Cancer
  • Giloblastoma
  • Malignant Meningioma
  • Mesothelioma
  • Melanoma
  • Others

By Top Selling Drugs

  • Revlimid
  • Avastin
  • Herceptin
  • Rituxan
  • Opdivo
  • Gleevec
  • Velcade
  • Imbruvica
  • Ibrance
  • Zytiga
  • Alimta
  • Xtandi
  • Tarceva
  • Perjeta
  • Termodar
  • Others

By Product Type

  • Chemotherapy
  • Radiation Therapy
  • Hormone Therapy
  • Biotherapy
  • Others

By End User

  • Consumption (Sales)
  • Household
  • Hospital

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global cancer therapeutics and biotherapeutics report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global cancer therapeutics and biotherapeutics market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Therapeutics and Biotherapeutics Market 

5.1. COVID-19 Landscape: Cancer Therapeutics and Biotherapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Therapeutics and Biotherapeutics Market, By Product

8.1. Cancer Therapeutics and Biotherapeutics Market, by Product Type, 2022-2030

8.1.1. Chemotherapy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Radiation Therapy

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Hormone Therapy

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Biotherapy

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cancer Therapeutics and Biotherapeutics Market, By End User

9.1. Cancer Therapeutics and Biotherapeutics Market, by End User, 2022-2030

9.1.1. Consumption (Sales)

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Household

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Hospital

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cancer Therapeutics and Biotherapeutics Market, By Application Type 

10.1. Cancer Therapeutics and Biotherapeutics Market, by Application Type, 2022-2030

10.1.1. Blood Cancer

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Lung Cancer

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Colorectal Cancer

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Prostate Cancer

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Breast Cancer

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Cervical Cancer

10.1.6.1. Market Revenue and Forecast (2017-2030)

10.1.7. Head and Neck Cancer

10.1.7.1. Market Revenue and Forecast (2017-2030)

10.1.8. Giloblastoma

10.1.8.1. Market Revenue and Forecast (2017-2030)

10.1.9. Malignant Meningioma

10.1.9.1. Market Revenue and Forecast (2017-2030)

10.1.10. Others

10.1.10.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cancer Therapeutics and Biotherapeutics Market, By Top Selling Drugs Type 

11.1. Cancer Therapeutics and Biotherapeutics Market, by Top Selling Drugs Type, 2022-2030

11.1.1. Revlimid

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Avastin

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Herceptin

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Rituxan

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Opdivo

11.1.5.1. Market Revenue and Forecast (2017-2030)

11.1.6. Others

11.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Cancer Therapeutics and Biotherapeutics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2017-2030)

12.1.2. Market Revenue and Forecast, by End User (2017-2030)

12.1.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.1.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.1.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.1.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.2.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.7.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.8.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.3.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.7.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.8.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.4.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.7.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.8.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.5.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.5.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.5.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Application Type (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)

Chapter 13. Company Profiles

13.1. Amgen Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bristol-Myers Squibb

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Celgene Corporation

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. ELI Lilly and Company

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Hoffmann-La Roche AG

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. EnGeneIC Ltd

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Merck & Co Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Novartis

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Pfizer Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Johnson & Johnson

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Tags:

Post a Comment

0 Comments